Global Skin Infection Market Overview:
Skin infection generally caused by fungus, bacteria, parasites and virus. This infection can be mild or severe depending on the infecting agent. Some of the symptoms of skin infection are discoloring and breakdown of the skin, blood blister, pus and others. Patients with diabetics, AIDS and others diseases are more prone to skin infections as these diseases lower the immune system of an individual and can cause life-threatening consequences. Some of the key players profiled in the study are 3M Company (United States), B. Braun Melsungen (Germany), Coloplast (Denmark), Genzyme Corporation (United States), Smith & Nephew (United Kingdom), ConvaTec Healthcare (United States), Human Biosciences Inc. (United States) and Melinta Therapeutics, Inc. (United States).
On the basis of geography, the market of Skin Infection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by by Treatment Type, the sub-segment i.e. Traditional Treatment will boost the Skin Infection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Skin Infection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence of Skin Infection Led to Growing Hygiene Awareness
- Developments in Biotechnology and Tissue Engineering
- Stringent Regulatory Guidelines on Production and Trade of Skin Infection Products
- Substandard Lifestyle and Poverty Led to Rise in Skin Infection Cases
- Growing Counterfeit Drugs Manufacturers
- Use of Homemade Remedies to Counter Skin Infection in Emerging Countries
"In 2013 the US Food and Drug Administration (FDA) issued recommendations and guidance on developing drugs for the treatment of skin infection using a new definition of acute bacterial skin and skin-structure infection (ABSSSI). The new classification includes cellulitis, erysipelas, major skin abscesses and wound infection with a considerable extension of skin involvement, clearly referring to a severe subset of skin infections. The main goal of the FDA was to better identify specific infections where the advantages of a new antibiotic could be precisely estimated through quantifiable parameters, such as improvement of the lesion size and of systemic signs of infection."
Skin infection market is fragmented owing to the presence of numerous players in the market. Companies are gradually focusing on the technological development for novel products and techniques for advanced and timely treatment of the skin infections creating lucrative opportunities for the skin infection market.
Target Audience:Healthcare Institute, Pharmaceutical Companies, Hospitals and Clinics, Drugs Manufacturers, Government bodies, Market research firms, Research Institutes and Others
Major Objectives Focused through this Study To define, describe, and forecast the Global Skin Infection market on the basis of product [Bacterial Skin Infection, Viral Skin Infection, Fungal Skin Infection and Parasitic Skin Infection] , application , key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Skin Infection market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Skin Infection industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Merck & Co., Inc. (United States), Allergan plc (United States) and Accord Healthcare Ltd. (United Kingdom).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Skin Infection market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.